Navigation Links
New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
Date:9/21/2010

ior. Depression assessments, as measured by the PHQ-9 clinical depression scale, improved from baseline for all treatment groups.

The incidence of targeted medical events for sleep disorders, depression, anxiety, cardiac disorders and cognitive disorders in SEQUEL was lower than observed during the one-year CONQUER study.

Similar to previously presented data, effects of QNEXA in SEQUEL on heart rate were small and seen in conjunction with improvements in blood pressure from baseline. There were no clinically relevant decreases of serum bicarbonate in QNEXA-treated patients compared to placebo in year two of SEQUEL.

Across the entire QNEXA development program (4,323 patients), including the two-year data in SEQUEL, serious cardiovascular and neurovascular adverse event rates in patients taking QNEXA were similar to placebo with a relative risk of 0.59 (95% CI: 0.33-1.06). No teratogenic effects were observed across the entire development program in patients taking QNEXA.

"These two-year data provide further reassurance that QNEXA may fill a significant medical need for this at-risk, co-morbid population struggling to lose weight and keep it off," said Leland Wilson, chief executive officer of VIVUS. "We look forward to presenting and publishing additional data from SEQUEL, including secondary efficacy endpoints for decreasing co-morbidity risks, in the future."

About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which together decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and imp
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology
2. Partnership for Quality Medical Donations Commits to Long-Term Recovery in Haiti
3. Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
4. FIRMAGON® Results in Fast, Long-Term Suppression of Testosterone in Prostate Cancer Patients Without Initial Testosterone Surge
5. FDA: Possible Fracture Risk With High Dose, Long-term Use of Proton Pump Inhibitors
6. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
7. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
8. Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study
9. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
10. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
11. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MOINES, Iowa , Jan. 23, 2015  The Partnership to Fight ... Iowa health care leaders and a new study analyzing ... medications. The PFCD is a nationwide coalition working to educate policy ... research released at the Capitol was focused on how the ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Show 26% Partial Response, 63% Clinical Benefit ... ... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today announced that its lead ... Phase 2,trial when administered in combination with trastuzumab (Herceptin(R)) to,patients with ...
... Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients, ... ENMD ), a clinical-stage pharmaceutical company developing,therapeutics ... today,announced the presentation of clinical data for the ... cancer. The data were presented by Bryan P.,Schneider, ...
Cached Medicine Technology:Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 3EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 4
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... a Boston based venture-backed technology startup has been ... Entrepreneurship Conference (WEC25). The WEC25 Expo is an ... products to a vast network of VCs and ... in the identity and access management industry to ...
... Feb. 4 Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ... for the first quarter of fiscal 2009, ended December 31, ... consolidated net loss of $7.6 million or $0.10 per share ... to revenues of $16.4 million and a consolidated net loss ...
... Hospitals of America (PHA) congratulates Congress on its ... healthcare access and insurance to millions of children ... "Congress recognized that the SCHIP bill was too ... address the contentious issue of physician ownership of ...
... Young Innovations, Inc.,(Nasdaq: YDNT ) today announced ... Sales for the fourth quarter of ... from the $25.0 million reported in the fourth quarter,of 2007. ... the,fourth quarter of 2007 to $4.8 million in the fourth ...
... LOS ANGELES, Feb. 4 The Elton John AIDS ... perform at the 17th Annual Elton John AIDS Foundation ... 2009, at the Pacific Design Center in Los Angeles. ... and David Furnish, and will be co-sponsored by Chopard, ...
... MedCath Corporation,(Nasdaq: MDTH ), a healthcare provider ... of cardiovascular disease,today announced its operating results for its first ... Highlights, -- Net revenue ... -- Adjusted EBITDA of $17.2 million, ...
Cached Medicine News:Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 2Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 3Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 2Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 3Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 4Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 5Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 6Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 7Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 8Health News:Physician Hospitals of America (PHA) Congratulates Congress on its Passage of a 'Clean' SCHIP Children's Health Bill 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 3Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 4Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 5Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 6Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 7Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 2Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 3Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 4Health News:MedCath Corporation Reports First Quarter Earnings 2Health News:MedCath Corporation Reports First Quarter Earnings 3Health News:MedCath Corporation Reports First Quarter Earnings 4Health News:MedCath Corporation Reports First Quarter Earnings 5Health News:MedCath Corporation Reports First Quarter Earnings 6Health News:MedCath Corporation Reports First Quarter Earnings 7Health News:MedCath Corporation Reports First Quarter Earnings 8Health News:MedCath Corporation Reports First Quarter Earnings 9Health News:MedCath Corporation Reports First Quarter Earnings 10Health News:MedCath Corporation Reports First Quarter Earnings 11Health News:MedCath Corporation Reports First Quarter Earnings 12Health News:MedCath Corporation Reports First Quarter Earnings 13Health News:MedCath Corporation Reports First Quarter Earnings 14
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: